Deqi Pharmaceuticals C round financing of $97 million, mainly for the development and commercialization of new drugs.

Guide: A number of investment and research institutions to help Deqi Medicine is committed to new drug research and development!Deqi Pharma, a leading company focused on developing and commercializing new mechanisms or best-in-class innovative drugs in the field of oncology, today announced the completion of a us$10,000 round of financingThis round of financing by the lead investment of other newly introduced investors including GaoYu Ventures, Singapore Government Investment Corporation () and a large well-known long-term institutional investors of existing investors, Qiming Ventures, Boyu Capital continued to participate"Thank you very much for the recognition and trust of our well-known investment institutionsThe round has been supported by investors from one of the world's largest asset managers and top investors in the healthcare industryThis financing is an important milestone for Deqi Pharmaceuticals, which will further bring more cutting-edge innovative therapies to patients in the Asia Pacific region and around the world in the face of serious life-threatening diseasesDrMei Jianming, founder, chairman and chief executive officer of Deqi Pharmaceuticals, saidThe financing will be used primarily to consolidate and strengthen the company's solid research and development pipeline to promote the continuous clinical development of blood tumors and solid tumor products to continue to enhance the ability of early drug in-house research and development and further enhance the company's commercial operations in the Asia-Pacific marketAt present, Deqi Pharma has established a rich research and development pipeline covering the clinical phase of the product and the first preclinical phase of the project and has made a number of significant progress: ( ) is the world's first oral selective nuclear output protein inhibitor ()The United States approved in january the combination of the treatment of recurrent multiple myeloma indications with low doses of dissemient emethanion () and approved a single drug for the treatment of recurrent diffuse large cell lymphoma ()A registered clinical study of refractor recurrent multiple myeloma and refractor lymphoma in relapsing diffuse large cell lymphoma is currently being conducted in ChinaTreatment options for the drug for a variety of other solid tumors (including mutated solid tumors) and blood tumors have also advanced into the late-clinical stagesPreclinical studies have shown that nuclei-exportprotein () inhibitors are effective in treating a variety of tumors that carry mutationsClinical studies on a variety of solid tumors, including colorectal cancer (), prostate cancer( and prostate cancer, are also being conducted simultaneously.The world's first dual-target inhibitors are conducting a number of clinical studies in tumorareas including non-Hodgkin's lymphoma (), colorectal cancer, non-small cell lung cancer, and melanomaIn addition, preclinical studies have shown that combination antibody therapy can be effective in improving anti-tumor efficacy and against antibody resistance in patientsClinical trials of health subjects have been completed A high-specific small molecule inhibitor is currently undergoing clinical studies on multiple solid tumors, non-Hodgkin's lymphoma, acute myeloid leukemia () and multiple myeloma In addition, deqi pharmaceutical early drug research and development team is continuing to promote small molecules, monoclonal and bispecific antibodies and other anti-tumor drugs preclinical research and development About Deqi Deqi Pharma is a China-based, Asia-Pacific-oriented, global integrated biopharmaceutical company focused on providing a cutting-edge, new and innovative anti-tumor therapy for patients in other countries and regions in Asia-Pacific and around the world New Foundation, the global leader in new drugs (now a world's top ten pharmaceutical company, has been formally acquired and merged by Baxter Squip, has become a founding partner of Deqi Pharmaceuticals and invests in Deqi Pharmaceuticals In the three years since its establishment, Deqi Pharmaceuticals has established a rich product pipeline with clinical and preclinical innovative drugs to obtain a clinical approval and conduct cross-regional clinical trials throughout Asia Pacific Deqi people with the "doctors without borders innovation and perpetuity" as the vision of the world's first and best-in-class research and market-oriented to solve the Asia-Pacific and even the world's unmet clinical needs of patients For more information, please visit 'About GaoGao Ventures, the venture capital fund focused on innovative companies is focused on biopharmaceuticals and medical devices, software services and primary technology innovation, consumer Internet and technology, emerging consumer brands and services in the four major areas of venture capital The field of biomedicine and medical devices has been the focus of gaogao's investment direction in recent years has been in-depth research investment in a number of excellent pharmaceutical, equipment enterprises including Baiji Shenzhou, Cinda Bio, Junshi Bio, Tianyi Biology, Fonda Pharmaceuticals, Namicro Technology, McCenter Medical, Pyche Medical, Puss Medical, Peijia Medical, Micro-Invasive Heart, Qiming Medical and so on We want to work with our friends who invest in business to help drive innovation and development in the big health sector to benefit more patients About GIC Isis Is the world's top investment company Established in the year to manage Singapore's foreign exchange reserves, the country and the people benefit in the long term As a long-term value investor, he has invested extensively in a wide range of asset classes including real estate, private equity, equities and fixed income Working with its fund managers and corporate management teams in private equity helps businesses through funds or direct investments in world-class companies Investing in emerging markets in several countries around the world has more than a year of experience Offices in 10 major financial centres and headquarters in Singapore employ more than one person For more information, please visit About Qiming Ventures () Qiming Ventures has established offices in Shanghai, Beijing, Suzhou, Shenzhen, Seattle, Boston and san Francisco Bay Area At present, Qiming Ventures manages nine US dollar funds with five RMB fund management assets of more than US$100 million Since its establishment, it has focused on investment, healthcare () and other industries early and long-term excellent enterprises Up to now, Qiming Ventures has invested more than a high-growth innovative enterprises, including more than the United States NYSE, NASDAQ Hong Kong Stock Exchange Taiwan Counter Buying Center Shanghai Stock Exchange and Shenzhen Stock Exchange and other exchanges listed and merged, such as the exit of a number of enterprises to become the industry recognized as unicorns and super unicorn enterprises Many of the most influential companies in The Xeming Ventures have grown into their respective fields, including Xiaomi Group (), American Group Reviews (), Beepa Beep (), Stone Technology (), Gan li Pharmaceuticals (), Tag Pharmaceuticals (Reding Pharmaceuticals) (), Qiming Medical (), Considine Bio (), Sanyou Medical (), Ed Bio (), Berry Gene (), Shenzhou Cell (), Micromedicine Group, Ande-Choice, etc About Boyu Capital Boyu Capital is one of the largest private equity firms in China With offices in Beijing, Shanghai and Hong Kong, Boyu provides long-term capital and operational advice to the best-managed and innovative companies in the media technology, medical, consumer retail and financial services industries